Abstract
In this case, we discuss emergent small bowel resection and reanastomosis for a closed loop small bowel obstruction in the setting of recent bevacizumab exposure. Bevacizumab is a humanized monoclonal antibody that binds to vascular endothelial growth factor, inhibiting angiogenesis, and decreasing tissue healing capacity, therefore recommendation is to avoid bevacizumab administration within 28 days pre- and postsurgery. Here we discuss emergent small bowel resection and reanastomosis for a closed loop small bowel obstruction in the setting of recent bevacizumab exposure. We review available literature regarding complication rates and discuss the challanges of management and counseling with this limited data available data on this topic. (J GYNECOL SURG 38:72)
Get full access to this article
View all access options for this article.